|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.2700 - 0.3000|
|52 Week Range||0.1990 - 2.2000|
|Beta (5Y Monthly)||4.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 18, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Subscribe to Yahoo Finance Plus to view Fair Value for MYCOFLearn more
Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that Josh Bartch, CEO of Mydecine, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.
Research to take place at Johns Hopkins, New York University and University of Alabama BirminghamDENVER, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it plans to supply its lead drug candidate, MYCO-001, for a multi-site smoking cessation study being conducted at Johns Hopkins University (“JHU”), Ne